

Our Ref: 489/2023  
October 2023

**Re: Your request made under the Freedom of Information Act 2000**

For the 4 months from May to August 2023, how many patients received the following intra-vitreous treatments for any eye condition:

Aflibercept - 834

Bevacizumab - 28

Brolucizumab - 0

Dexamethasone - 11

Faricimab - 79

Ranibizumab – Lucentis - 12

Ranibizumab – Ongavia - 1